Hypertension Treatment Adherence Improving Trial

Sponsor
The Hong Kong Polytechnic University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04565548
Collaborator
(none)
148
2
2
5.9
74
12.6

Study Details

Study Description

Brief Summary

Persistent adherence to lifestyle modifications and blood pressure lowering medications were the best way to control blood pressure. But low adherence was noted in reviews and studies resulting those taking blood pressure lowering medications could not achieve a controlled blood pressure. In this study, a theory-guided educational program will be developed with an aim to improve the blood pressure, self-efficacy and adherence behaviors among those diagnosed with high blood pressure in the community. 148 participants will be recruited and divided into control group and intervention group randomly in a ratio of 1:1. The intervention group will receive the theory-guided educational program, while the control group will receive the usual care. The study will last for 12 weeks. Data will be collected at baseline, week 8 and week 12. SPSS and generalized estimating equations model will be employed for data analysis. The results will inform an effective way to conduct health promotion in community. The improved adherence to lifestyle modifications and medications will be beneficial to the clients' health.

Condition or Disease Intervention/Treatment Phase
  • Other: Educational program for hypertensive patients
  • Other: Usual care
N/A

Detailed Description

Persistent adherence to lifestyle modifications and anti-hypertensive medications were emphasized in hypertension guidelines to control blood pressure effectively. But low adherence to lifestyle modifications and medication were noted in reviews and studies. Low adherence would lead to those received hypertension treatment did not achieve a controlled blood pressure. In this study, an educational program guided by the Health Promotion Model will be conducted to examine the effect on blood pressure, self-efficacy and treatment adherence among hypertensive patients in the community. A 2-arm parallel randomized control trial will be conducted. 148 participants will be recruited and divided into control and intervention group in a ration of 1:1. The intervention group will receive the theory-guided educational program, while the control group will receive the usual care. The study will last for 12 weeks. Data will be collected at baseline, week 8 and week 12. SPSS and generalized estimating equations model will be employed for data analysis. The results will inform community healthcare professionals about the effective way for health promotion, to enhance the adherence to lifestyle modifications and medications among hypertensive clients resulting sustainable benefits to the clients' health.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
148 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcomes assessors will not participate in group allocation or intervention delivery.
Primary Purpose:
Other
Official Title:
Effect of an Educational Program for Hypertensive Patients: a Randomized Controlled Trial
Actual Study Start Date :
Mar 6, 2021
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Participants will receive the newly developed theory-guided program for 12 weeks.

Other: Educational program for hypertensive patients
The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.

Active Comparator: Control

Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.

Other: Usual care
One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.

Outcome Measures

Primary Outcome Measures

  1. Change of blood pressure at week 8 and week 12 [Baseline, week 8, week 12]

    Systolic and diastolic blood pressure (mmHg) is measured by a trained research assistant. A validated upper-arm blood pressure monitor is used for the blood pressure measurement.

Secondary Outcome Measures

  1. Change of Treatment Adherence Questionnaire for Patients with Hypertension (TAQPH) at week 8 and week 12 [Baseline, week 8, week 12]

    TAQPH consists of 28 items and covers the adherence to medications and lifestyle modifications in hypertension management. The responses are made on a 1-4 scale, and the sum of the score ranges from 28 to 112. The TAQPH has been proved to be reliable with good Cronbach's alpha coefficient 0.86 for Chinese hypertensive adults.

  2. Change of Self-efficacy for managing chronic disease (SEMCD) at week 8 and week 12 [Baseline, week 8, week 12]

    SEMCD consists of six self-report items to measure the self-efficacy of hypertension management. Summative scores range from 6 to 60. The scale was translated into Chinese and yielded a good reliability (Cronbach's alpha = 0.88-0.98; teste-retest reliability = 0.73-0.98) in Chinese hypertensive adults and Chinese older adults.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Own a mobile phone and able to use

  • Able to communicate with Cantonese and read Chinese

  • Diagnosed with hypertension and taking at least one anti-hypertensive medication

  • SBP = 131159 mmHg or DBP = 8199 mmHg

Exclusion Criteria:
  • Renal hypertension

  • Mini-Cog < 3

Contacts and Locations

Locations

Site City State Country Postal Code
1 Community Health Centres Shenzhen Shenzhen China 00
2 Complexo de Apoio à Família e de Serviço Comunitário de Seac Pai Van da União Geral das Associações dos Moradores de Macau Kowloon Hong Kong

Sponsors and Collaborators

  • The Hong Kong Polytechnic University

Investigators

  • Principal Investigator: Eliza Mi Ling Wong, Dr, Hong Kong Polytechnic University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Hong Kong Polytechnic University
ClinicalTrials.gov Identifier:
NCT04565548
Other Study ID Numbers:
  • HSEARS20200821002
First Posted:
Sep 25, 2020
Last Update Posted:
Aug 4, 2021
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Hong Kong Polytechnic University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2021